119 related articles for article (PubMed ID: 9830618)
1. Recent advances in oral fluoropyrimidine therapies. Proceedings of a meeting. Chicago, Illinois, USA. July 11, 1998.
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):9-56. PubMed ID: 9830618
[No Abstract] [Full Text] [Related]
2. Biochemical and clinical pharmacology of 5-fluorouracil.
Schilsky RL
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):13-8. PubMed ID: 9830619
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
Iyer L; Ratain MJ
Cancer Invest; 1999; 17(7):494-506. PubMed ID: 10518194
[No Abstract] [Full Text] [Related]
4. No circadian variation of dihydropyrimidine dehydrogenase, uridine phosphorylase, beta-alanine, and 5-fluorouracil during continuous infusion of 5-fluorouracil.
Van Kuilenburg AB; Poorter RL; Peters GJ; Van Gennip AH; Van Lenthe H; Stroomer AE; Smid K; Noordhuis P; Bakker PJ; Veenhof CH
Adv Exp Med Biol; 1998; 431():811-6. PubMed ID: 9598176
[No Abstract] [Full Text] [Related]
5. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
6. Estimation of dihydropyrimidine dehydrogenase activity: does it have a role in cancer therapy?
Collie-Duguid ES; McLeod HL; Cassidy J
Ann Oncol; 2000 Mar; 11(3):255-7. PubMed ID: 10811489
[No Abstract] [Full Text] [Related]
7. Toxicity of 5-fluorouracil.
Macdonald JS
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):33-4. PubMed ID: 10442356
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
9. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
Schneider HB; Becker H
Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
[TBL] [Abstract][Full Text] [Related]
10. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology.
Diasio RB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):23-7. PubMed ID: 9830621
[TBL] [Abstract][Full Text] [Related]
11. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy.
Zhang X; Diasio RB
Pharmacogenomics; 2007 Mar; 8(3):257-65. PubMed ID: 17324113
[TBL] [Abstract][Full Text] [Related]
12. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
13. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
14. Fluoropyrimidine catabolism.
Diasio RB; Lu Z; Zhang R; Shahinian HS
Cancer Treat Res; 1995; 78():71-93. PubMed ID: 8595148
[No Abstract] [Full Text] [Related]
15. Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil.
Diasio RB
Clin Adv Hematol Oncol; 2016 Jul; 14(7):510-2. PubMed ID: 27379945
[No Abstract] [Full Text] [Related]
16. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
Innocenti F; Ratain MJ
Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
[No Abstract] [Full Text] [Related]
17. [Intratumoral dihydropyrimidine dehydrogenase and its inhibition: a new approach in the pharmacokinetics of 5-fluorouracil].
Milano G; Etienne MC; Fischel JL
Ann Gastroenterol Hepatol (Paris); 1995; 31(2):103-5. PubMed ID: 7618831
[No Abstract] [Full Text] [Related]
18. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
Diasio RB; Johnson MR
Clin Cancer Res; 1999 Oct; 5(10):2672-3. PubMed ID: 10537327
[No Abstract] [Full Text] [Related]
19. Clinical development of eniluracil: current status.
Hohneker JA
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting 5-fluorouracil breakdown: a broken down approach to 5-fluorouracil modulation.
Schilsky RL
Clin Colorectal Cancer; 2002 May; 2(1):51-2. PubMed ID: 12453336
[No Abstract] [Full Text] [Related]
[Next] [New Search]
